BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 24, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 12/21 cls
Alkermes (ALKS) Banc of America Securities William Ho New Buy 8% $15.86
Ho set an $18 target. He believes exenatide LAR to treat Type II diabetes is a potential blockbuster based on positive data from a 30-week, open-label trial presented by partner Amylin (AMLN) (see BioCentury, Nov. 5). He also expects Phase III data for inhaled AIR Insulin powder from ALKS and partner Eli Lilly (LLY) in 4Q08, with a potential launch in 2010.
Alnylam (ALNY) Broadpoint Simos Simeonidis New Buy -1% $29.92
Simeonidis set a $38 target. He believes RNAi "represents a potentially transformational technology" and that ALNY is a leader in the space.
Altus (ALTU) Collins Stewart Andrew Fein Downgrade Market perform (from buy) -47% $5.44
Fein downgraded the stock after Genentech (DNA) returned rights to ALTU-238, a subcutaneous long-acting formulation of somatropin recombinant human growth hormone (see B3).
Anesiva (ANSV) Rodman Elemer Piros Price target Market outperform 11% $4.44
Piros lowered his target to $6 from $11 after ANSV raised $45M through the sale of 11.1M shares at $4.05. He said the price was lower than he expected, which resulted in more dilution (see "Pain Relief," A14).
Array BioPharma (ARRY) Banc of America Securities William Ho Price target Buy -21% $8.70
Collins Stewart Andrew Fein Other

Read the full 1357 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >